NCT02954523 - Dasatinib and Osimertinib (AZD9291) in Advanced Non-Small Cell Lung Cancer With EGFR Mutations | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2016

Primary Completion Date

August 31, 2018

Study Completion Date

March 3, 2023

Conditions

EGFR Gene MutationNonsmall Cell Lung Cancer

Interventions

DRUG

Dasatinib

oral every day

DRUG

Osimertinib

oral every day

Trial Locations (2)

Georgetown Lombardi Comprehensive Cancer Center, Washington D.C.

John Theurer Cacner Center at Hackensack University Medical Center, Hackensack